Interferon beta-1a for COVID-19: critical importance of the administration route

Overview of attention for article published in Critical Care, June 2020

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (93rd percentile)
High Attention Score compared to outputs of the same age and source (84th percentile)

So far, Altmetric has seen 6 news stories from 4 outlets.

Company announcement, 14 May 2021 at 9.00 AM (EEST) TURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON)…

RNS Number : 6023Y Faron Pharmaceuticals Oy 14 May 2021 Faron Pharmaceuticals Oy ("Faron" or the "Company") Faron secures U.S.

("Faron" or the "Company") Faron secures U.S. rights to patent related to Traumakine Company announcement, 14 May 2021 at 9.00…

First Results from WHO Solidarity Trial WHO concludes that subcutaneous IFN beta-1a is ineffective in hospitalized COVID-19…

RNS Number : 3540C Faron Pharmaceuticals Oy 16 October 2020 Faron Pharmaceuticals Oy ("Faron" or the "Company") WHO concludes…

concludes that subcutaneous IFN beta-1a is ineffective in hospitalized COVID-19 patients ("Faron" or the "Company") Company…